EUVIMEDEUVIMED entdecken
Crossref

Long-term benefits of policosanol plus low dose of aspirin in the functional recovery of non-cardiogenic ischemic stroke: A randomized, placebo-controlled study

Langfristiger Nutzen von Policosanol plus niedriger Aspirindosis für die funktionelle Erholung nach nicht-kardiogenem ischämischem Schlaganfall: randomisierte placebokontrollierte Studie

Javier Vicente Sánchez López, Julio César Fernández Travieso, Yenney Reyes Nuñez, Enmanuel Zayas Fundora, Jose Leandro Rubalcaba La Rosa, Yurisan Almenarez Campos, Elio Chávez Chávez, Yanay Fernández Domínguez, Evelyn Anie González Pla, Sarahí Mendoza Castaño, Gladys Jiménez Rivero, Delia Maria Galvez Medina und 1 weitere

Advanced Neurology · 26.06.2026 · 5 (4) · 025410094

DOI: 10.36922/an025410094 ↗

Auf einen Blick

Bei Patient:innen mit frischem nicht-kardiogenem ischämischem Schlaganfall führte Policosanol plus ASS 81 mg/Tag über 12 Monate zu besserer funktioneller Erholung als Placebo plus ASS 81 mg/Tag.

Fragestellung

Verbessert Policosanol 20 mg/Tag plus ASS 81 mg/Tag im Vergleich zu Placebo plus ASS 81 mg/Tag die funktionelle Erholung nach nicht-kardiogenem ischämischem Schlaganfall?

Methode

Randomisierte, doppelblinde, placebokontrollierte Studie; Patient:innen mit NCIS ≤30 Tage und mRS 2–3; Behandlung 12 Monate.

Ergebnisse

Von 100 randomisierten Patient:innen schlossen 98 die Studie ab. mRS ≤1 erreichten 46/50 (92 %) unter Policosanol/ASS vs. 23/50 (46 %) unter Placebo/ASS. mRS und BI verbesserten sich unter Policosanol/ASS (p < 0,01).

Schlussfolgerung der Autor:innen

Policosanol 20 mg/Tag plus ASS 81 mg/Tag verbesserte nach Angaben der Autor:innen die funktionelle Erholung nach NCIS im Vergleich zu Placebo/ASS.

Kernaussagen

  • mRS ≤1: 92 % vs. 46 %
  • mRS und Barthel-Index verbesserten sich unter Policosanol/ASS
  • Lipidprofil und Verträglichkeit wurden ebenfalls günstig berichtet

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Neurology, online erschienen am 26.06.2026. Verfasst von Javier Vicente Sánchez López und 12 weiteren Autor:innen.

Auf einen BlickAbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stroke is one of the main causes of mortality and disability worldwide. Previous studies have demonstrated the benefits of policosanol 20 mg/day (poli 20) + aspirin (AS) 125 mg/day on functional recovery after a non-cardiogenic ischemic stroke (NCIS), but the effects of poli 20 + lower doses of AS have not yet been studied. This randomized, double-blind study investigates the long-term effects of poli 20 + AS 81 mg/day (poli/AS) or placebo + AS 81 mg/day (pla/AS) on functional recovery after an NCIS. Patients who have suffered a recent (≤30 days from stroke onset) NCIS and with a modified Rankin Scale (mRS) score of 2–3 were randomized to receive either poli/AS or pla/AS for 12 months. The primary outcome was whether the frequency of patients in the poli/AS group achieving an mRS score ≤ 1 was higher than that in the pla/AS group. Secondary outcomes included changes in mean mRS and Barthel Index (BI) scores between the poli/AS and pla/AS groups. Effects on lipid profile were collateral outcomes. Of 100 randomized patients, 98 patients completed the study. Missing data from the two remaining patients were handled using single imputation with the last-observation-carried-forward method. Results demonstrated that significantly more poli/AS patients (46/50; 92%) achieved an mRS score ≤ 1 than pla/AS patients (23/50; 46%). Poli/AS significantly reduced the mean mRS score and increased BI score (p < 0.01) compared with baseline and pla/AS. Lipid profile benefits and good tolerability were confirmed. It is demonstrated for the first time that treatment with poli 20 mg/day plus a lower dose of AS (81 mg/day) significantly improved functional recovery following an NCIS compared with pla/AS.

Zitieren

APA

López, J. V. S., Travieso, J. C. F., Nuñez, Y. R., Fundora, E. Z., Rosa, J. L. R. L., Campos, Y. A., Chávez, E. C., Domínguez, Y. F., Pla, E. A. G., Castaño, S. M., Rivero, G. J., Medina, D. M. G., & García, M. R. (2026). Long-term benefits of policosanol plus low dose of aspirin in the functional recovery of non-cardiogenic ischemic stroke: A randomized, placebo-controlled study. Advanced Neurology, 5(4), 025410094. https://doi.org/10.36922/an025410094

Vancouver

López JVS, Travieso JCF, Nuñez YR, Fundora EZ, Rosa JLRL, Campos YA, et al. Long-term benefits of policosanol plus low dose of aspirin in the functional recovery of non-cardiogenic ischemic stroke: A randomized, placebo-controlled study. Advanced Neurology. 2026;5(4):025410094. doi:10.36922/an025410094

BibTeX
@article{Lpez2026,
  author = {López, Javier Vicente Sánchez and Travieso, Julio César Fernández and Nuñez, Yenney Reyes and Fundora, Enmanuel Zayas and Rosa, Jose Leandro Rubalcaba La and Campos, Yurisan Almenarez and Chávez, Elio Chávez and Domínguez, Yanay Fernández and Pla, Evelyn Anie González and Castaño, Sarahí Mendoza and Rivero, Gladys Jiménez and Medina, Delia Maria Galvez and García, Maytee Robaina},
  title = {Long-term benefits of policosanol plus low dose of aspirin in the functional recovery of non-cardiogenic ischemic stroke: A randomized, placebo-controlled study},
  journal = {Advanced Neurology},
  year = {2026},
  volume = {5},
  number = {4},
  pages = {025410094},
  doi = {10.36922/an025410094}
}
Kostenlos starten →